IART's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 259.28 -- higher than 87.91% of US-listed equities with positive expected earnings growth.
With a price/earnings ratio of 83.01, Integra Lifesciences Holdings Corp P/E ratio is greater than that of about 89.6% of stocks in our set with positive earnings.
In terms of volatility of its share price, IART is more volatile than merely 6.36% of stocks we're observing.
Stocks with similar financial metrics, market capitalization, and price volatility to Integra Lifesciences Holdings Corp are CW, MTSC, HRC, CMCO, and PNR.
Integra LifeSciences Holdings Corporation (IART) Company Bio
Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.
IART Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Integra Lifesciences Holdings Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Integra Lifesciences Holdings Corp ranked in the 48th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 3.5%. As for the metrics that stood out in our discounted cash flow analysis of Integra Lifesciences Holdings Corp, consider:
Its compound free cash flow growth rate, as measured over the past 5.67 years, is 0.3% -- higher than 67.87% of stocks in our DCF forecasting set.
Integra Lifesciences Holdings Corp's effective tax rate, as measured by taxes paid relative to net income, is at 14 -- greater than 54.67% of US stocks with positive free cash flow.
Relative to other stocks in its sector (Healthcare), Integra Lifesciences Holdings Corp has a reliance on debt greater than 70.06% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Integra Lifesciences Holdings Corp? See PAHC, FONR, LNTH, LCI, and INBP.
Integra LifeSciences (IART) to sell its Extremity Orthopedics business to Smith+Nephew (SNN) for $240M in cash.The transaction is expected to close at or around the end of 2020 and will not have a material impact on 2020 financial results. The Extremity Orthopedics business generated revenues of $90M in 2019 and ~$32.7M...
The Global Intracranial Pressure Monitoring Market Research Report offers an in-depth analysis of the Intracranial Pressure Monitoring industry and the economic scenario for business management that offers development and profitability for the key players in the market. The report on
DBMR has added a new report titled Global Metacarpel Joint Implants Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Global Metacarpel Joint
DUBLIN--(BUSINESS WIRE)--The "Digits Replacement (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. This market model discusses in detail the impact of COVID-19 on Digits Replacement market for the year 2020 and beyond. Companies Mentioned Integra LifeSciences Corp. Stryker Corp. Wright Medical Group N.V. KLS Martin L.P. Although fusion is often still considered the treatment of choice the new ge